文献速递主动脉疾病内脏/肾动脉与血管畸形

胸腹主动脉疾病血管内治疗中有意覆盖腹腔干的安全性与疗效:系统评价与Meta分析

Safety and Efficacy of Intentional Celiac Artery Coverage in Endovascular Management of Thoracoabdominal Aortic Diseases: A Systematic Review and Meta-analysis.
PubMed 文献 · J Endovasc Ther · 2021-11-26

该系统评价与Meta分析纳入2009至2020年发表的10项观察性队列研究、共175例患者,评估胸腹主动脉疾病TEVAR中覆盖腹腔干的安全性与疗效。30天死亡率为5%(95%CI 2%-13%),再干预率9%,肠系膜缺血6%,脊髓缺血7%。作者认为覆盖腹腔干是具挑战但可行的选择,术前证实内脏侧支循环充分是技术成功的必要条件。

要点

  • TEVAR中覆盖腹腔干的30天死亡率为5%(95%CI 2%-13%),总体死亡率为21%(95%CI 14%-31%)。
  • 再干预率9%、脊髓缺血7%、肠系膜缺血6%,II型内漏最常见(10%)。
  • 作者认为覆盖腹腔干具挑战但可行,术前证实内脏侧支循环充分是成功必要条件。

核心结论

  • 作者认为TEVAR中覆盖腹腔干治疗胸腹主动脉疾病具挑战但可行,并发症与死亡率可接受。
  • 作者认为在最终覆盖腹腔干前证实内脏侧支循环充分是该技术成功的必要条件。

研究设计与样本

  • 系统评价与Meta分析,按PRISMA指南检索MEDLINE与SCOPUS数据库。
  • 纳入2009至2020年发表的10项观察性队列研究,共175例患者。
  • 主要终点为围手术期与30天死亡率,次要终点包括各型内漏、肠系膜缺血、围手术期脊髓缺血与再干预率。
  • 采用随机效应Meta分析,事件风险汇总统计量以比例和95%CI表示。

主要发现

  • TEVAR指征:原发性胸腹主动脉瘤82%患者、主动脉夹层14%患者、既往内移植物置入后Ib型内漏3%患者、穿透性主动脉溃疡1例患者。
  • 再干预率9%(95%CI 4%-20%),脊髓缺血7%(95%CI 4%-12%)。
  • II型内漏最常见,占10%患者(95%CI 4%-22%);I型内漏占5%患者(95%CI 2%-12%);III型内漏占1%患者(95%CI 0%-16%)。
  • 肠系膜缺血发生于6%患者(95%CI 3%-10%)。
  • 30天死亡率5%(95%CI 2%-13%),总体死亡率汇总估计为21%(95%CI 14%-31%)。

关键数值与推荐

  • TEVAR中覆盖腹腔干后30天死亡率为5%(95%CI 2%-13%)。
  • 总体死亡率汇总估计为21%(95%CI 14%-31%)。
  • 再干预率9%(95%CI 4%-20%),脊髓缺血7%(95%CI 4%-12%),肠系膜缺血6%(95%CI 3%-10%)。
  • II型内漏10%患者(95%CI 4%-22%),I型内漏5%患者(95%CI 2%-12%),III型内漏1%患者(95%CI 0%-16%)。

临床怎么用

  • 作者认为TEVAR中覆盖腹腔干治疗胸腹主动脉疾病是具挑战但可行的选择,并发症与死亡率可接受。
  • 作者认为在最终覆盖腹腔干前证实内脏侧支循环充分是该技术成功的必要条件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Thoracic endovascular aortic aneurysm repair (TEVAR) has emerged as an attractive alternative option in the treatment of thoracoabdominal aortic aneurysm (TAAA) diseases, reporting lower morbidity and mortality rates compared with open or hybrid repair. A challenging situation arises when the aneurysm involves the celiac artery (CA), precluding a safe distal landing zone. We investigated the safety and efficacy of CA coverage in the treatment of complex TAAA diseases during endovascular management. MATERIALS AND METHODS: A review of the literature was conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. The electronic bibliographic sources searched were MEDLINE and SCOPUS databases. Primary outcomes of interest were perioperative and 30-day mortality. Any type of endoleak, mesenteric ischemia, perioperative spinal cord ischemia, and reintervention rates were secondary end points. A random-effects meta-analysis was performed. Summary statistics of event risks were expressed as proportions and 95% confidence interval (CI). RESULTS: Ten observational cohort studies published between 2009 and 2020, reporting a total of 175 patients, were eligible for quantitative synthesis. Indications for TEVAR were primary TAAAs in 82% of patients, aortic dissection in 14% of patients, type Ib endoleak after previous endograft deployment in 3% of patients, and penetrating aortic ulcer in 1 patient. Reintervention rate was 9% (95% CI, 4%-20%) and spinal cord ischemia was 7% (95% CI, 4%--12%). Type II endoleak was the predominant type of endoleak in 10% of patients (95% CI, 4%-22%), followed by type I endoleak in 5% of patients (95% CI, 2%-12%) and type III endoleak in 1% (95% CI, 0%-16%) of patients. Mesenteric ischemia occurred in 6% of patients (95% CI, 3%-10%). Thirty-day mortality was 5% (95% CI, 2%-13%) and the pooled estimate for overall mortality was 21% (95% CI, 14%-31%). CONCLUSIONS: Celiac artery coverage during TEVAR is a challenging but feasible option for the treatment of TAAA diseases, providing acceptable morbidity and mortality rates. Demonstration of adequate visceral collateral pathways before definitive CA coverage is the sine quo non for the success of the technique.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Argyriou C, Spiliopoulos S, Katsanos K, et al. Safety and Efficacy of Intentional Celiac Artery Coverage in Endovascular Management of Thoracoabdominal Aortic Diseases: A Systematic Review and Meta-analysis. J Endovasc Ther. 2021. PMID: 34836463. doi:10.1177/15266028211059451

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。